Navigation Links
Tumor cells in blood may signal worse prognosis in head and neck cancer patients
Date:12/21/2010

COLUMBUS, Ohio A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival. An increased number of circulating tumor cells (CTCs) also correlates with a worse outcome.

Those are the early findings from an ongoing, prospective study of the prognostic importance of CTCs by a team of researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The study is published in the Dec. issue of the Archives of Otolaryngology, Head and Neck Surgery.

"These findings are extremely exciting, and they suggest that the presence of circulating tumor cells in the blood is correlated with reduced disease-free survival," says co-first author Dr. Kris Jatana, assistant professor of otolaryngology-head and neck surgery at The Ohio State University and Nationwide Children's Hospital. "If these results are supported with continued prospective follow-up, CTCs would be used as a prognostic marker to help further individualize therapy."

Squamous cell carcinomas make up 95 percent of the 36,500 new cases of head and neck cancer expected to occur in the United States in 2010, and the estimated 7,900 deaths from the disease. Currently, no prognostic blood test exists for this malignancy.

With 5 billion red blood cells and 7 million white blood cells in just 20 drops of blood (that is, in one milliliter), counting the much-smaller number of CTCs that might be in a patient blood sample specimen is a challenge.

This team of researchers identified CTCs after first removing normal cells so that abnormal cellscancer cellsremained, a method called negative depletion. They eliminated all the red blood cells by rupturing them, then removed healthy white blood cells by labeling them with magnetic nanoparticles and used a strong magnetic field to pull them out of each sample. Finally, the remaining abnormal cells were stained and manually counted.

"We believe our technique is superior to others because it removes normal cells from the blood, allowing for the detection of CTCs in their native state," Jatana says. "Other reported techniques identify only those cells with a specific surface marker, which has the potential to miss abnormal cells."

This study involves 48 patients who underwent surgical intervention for squamous cell cancer of the head and neck, 35 of which had smoked the equivalent of a pack of cigarettes a day for 15 years, and half of them were moderate to heavy alcohol consumers.

"Although smoking and alcohol consumption are a contributing risk factor for developing head and neck cancers, patients who do not use either also can develop the disease," Jatana says. Patients in the study were followed for an average of 19 months after surgery.

To date, no instances of cancer recurrence or disease-related mortality occurred in patients with no CTCs. The study found a correlation between an increasing number of CTCs and a worse prognosis.

"In the future, along with continued follow-up of these patients, we want to further characterize these cells and determine if this technology can be used for early detection of cancer recurrence," Jatana says. "This could help us individualize treatment and optimize outcomes for head and neck cancer patients."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers discover new way to kill pediatric brain tumors
2. Researchers create drug to keep tumor growth switched off
3. Fluorescent probes light up cancerous tumors
4. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
5. Drug for advanced kidney cancer shrinks tumors prior to surgery
6. Researchers discover second protective role for tumor-suppressor
7. Personalizing cancer: Creating biomarkers from tumor DNA
8. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
9. Tumor mechanism identified
10. Mayo oral cancer study shows full tumor genome
11. How estrogen feeds breast tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: